ORKAHealthcare · BiotechnologyORKA Stock Forecast: Oruka Therapeutics, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Oruka Therapeutics, Inc. hold a median 12-month price target of $151 — +58.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 1 Aug 2026 — in the lower half.
ORKA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Oruka Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (100): The shares have been drifting up relative to others.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Oruka Therapeutics, Inc. — and when they’d sell — is the membership.
ORKA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ORKA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +58.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | BTIG | Reiterates | Buy | $151 |
| 1 July 2026 | UBS | Maintains | Buy | — |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | BTIG | Reiterates | Buy | — |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Apr 2026 | Barclays | Maintains | Overweight | — |
| 28 Apr 2026 | UBS | Maintains | Buy | — |
| 27 Apr 2026 | BTIG | Maintains | Buy | — |
| 15 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 13 Apr 2026 | BTIG | Maintains | Buy | — |
| 13 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 7 Apr 2026 | Barclays | Maintains | Overweight | — |
| 6 Apr 2026 | Guggenheim | Maintains | Buy | — |
| 6 Apr 2026 | UBS | Maintains | Buy | — |
| 16 Mar 2026 | Leerink Partners | Maintains | Outperform | — |
| 13 Mar 2026 | Barclays | Maintains | Overweight | — |
| 13 Mar 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ORKA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Oruka Therapeutics, Inc. (ORKA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −52.1×
- Price / sales
- —
- Price / book
- 10.0×
- EV / EBITDA
- −40.8×
Cheaper than 98% of US stocks
Cheaper than 10% of US stocks
Cheaper than 93% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −27.3%
- Return on assets
- −18.9%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ORKA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORKA appears on the weeks it earns a place.
Frequently asked questions about ORKA stock
What is the ORKA stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Oruka Therapeutics, Inc. have a median 12-month price target of $151, with estimates ranging from $102 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ORKA stock a buy right now?
Of the 13 analysts covering Oruka Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oruka Therapeutics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ORKA?
As at 1 Aug 2026, Oruka Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).
Will ORKA stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +58.8% from the last close, and Ticker Nerd's factor model ranks Oruka Therapeutics, Inc. 48 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ORKA stock forecast for 2030?
No analyst covering Oruka Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORKA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $102 to $200 over the next 12 months.
How has ORKA stock performed over the past year?
Oruka Therapeutics, Inc. returned +597.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oruka Therapeutics, Inc. do?
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead product, ORKA-001, targets the p19 subunit of interleukin-23 and is in Phase 2 trials for moderate-to-severe psoriasis, featuring half-life extension technology that supports potential once-per-year dosing. The co-lead program, ORKA-002, targets interleukin-17A and interleukin-17F for psoriasis, psoriatic arthritis, and conditions like hidradenitis suppurativa, with Phase 1 data indicating a half-life of 75-80 days to enable twice-yearly or quarterly dosing. The company also advances ORKA-003 targeting an undisclosed pathway. These biologics aim to provide high-affinity binding, extended exposure, and reduced dosing frequency to improve patient outcomes in chronic skin and autoimmune diseases. Founded in 2004 and headquartered in Menlo Park, California, Oruka Therapeutics operates in the biotechnology sector, focusing on dermatology and immunology pipelines to address unmet needs in the inflammatory disease market.
CEO Dr. Lawrence Otto Klein Ph.D. · 68 employees · United States · https://orukatx.com